Susan M. Lotarski

Behavioral Characterization of A53T Mice Reveals Early and Late Stage Deficits Related to Parkinson’s Disease

Katrina L. Paumier, Stacey J. Sukoff Rizzo, Zdenek Berger et al. · PLoS ONE · 2013 · 185 citations · Full text

Negative allosteric modulation of metabotropic glutamate receptor 5 results in broad spectrum activity relevant to treatment resistant depression

Zoë A. Hughes, Sarah J. Neal Webb, Daniel L. Smith et al. · Neuropharmacology · 2012 · 85 citations

Psychiatry, Negative Allosteric Modulation, Treatment Resistant Depression +12

Discovery of the Potent and Selective M1 PAM-Agonist<i>N</i>-[(3<i>R</i>,4<i>S</i>)-3-Hydroxytetrahydro-2<i>H</i>-pyran-4-yl]-5-methyl-4-[4-(1,3-thiazol-4-yl)benzyl]pyridine-2-carboxamide (PF-06767832): Evaluation of Efficacy and Cholinergic Side Effects

Jennifer E. Davoren, Che‐Wah Lee, Michelle R. Garnsey et al. · Journal of Medicinal Chemistry · 2016 · 83 citations · Full text

Positive Allosteric Modulation of AMPA Receptors from Efficacy to Toxicity: The Interspecies Exposure-Response Continuum of the Novel Potentiator PF-4778574

Christopher L. Shaffer, Raymond S Hurst, Renato J. Scialis et al. · Journal of Pharmacology and Experimental Therapeutics · 2013 · 61 citations

Design and Synthesis of γ- and δ-Lactam M₁ Positive Allosteric Modulators (PAMs): Convulsion and Cholinergic Toxicity of an M₁-Selective PAM with Weak Agonist Activity

Jennifer E. Davoren, Michelle R. Garnsey, Betty Pettersen et al. · Journal of Medicinal Chemistry · 2017 · 58 citations · Full text